Komori
KYORIN Pharmaceutical (4569) · InitiativeRestated

Strengthening Oversight by Outside Directors

First written in FY2017. 4 of 5 entries say "Restated". Latest entry: 2026-05-28.

5entries
10years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – 2026-05-282017: 120172018: 120182019: 120192020: 020202021: 020212022: 020222023: 020232024: 120242025: 020252026: 12026
Same theme, other companies
Strengthening management oversight through the appointment of outside directorsA theme 37 companies write about · 0 as a headwind · 37 as a tailwind

14 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 37 companies compared. The sentences above are computed from all 37.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-28RestatedGeneral Meetings of Shareholders

    「The composition of the Board of Directors if the proposals are approved as originally submitted at this Annual General Meeting of Shareholders, and the skills held by each director and Audit & Supervisory Board member, are as follows.」

    The composition of the Board, including outside and independent director candidates, and the skills matrix were presented, reconfirming a structure emphasizing oversight and transparency.
  2. FY2024RestatedAnnual report

    「Our Board of Directors comprises 6 directors, including 3 independent outside directors, and generally meets regularly once a month to resolve statutory matters, formulate and determine important management policies and strategies, and oversee the execution of operations.」

    The company continues its oversight structure through a 6-member Board of Directors, including 3 independent outside directors, with regular meetings held once a month.
  3. FY2019RestatedAnnual report

    「We have appointed 3 independent outside directors, seek their advice from an independent and objective standpoint at Board of Directors meetings and elsewhere, and maintain an effective management oversight structure that keeps a certain distance from the execution of operations.」

    The company continues its advice and oversight structure involving 3 independent outside directors.
  4. FY2018RestatedAnnual report

    「To further strengthen oversight of the directors' execution of duties and enhance management transparency and fairness, we have appointed 3 outside directors.」

    The company continues to strengthen oversight and transparency through 3 outside directors.
  5. FY2017First statedAnnual report

    「At the annual general meeting of shareholders held in June 2017, we elected 3 outside directors and will use their independence, extensive experience and high level of expertise to strengthen management transparency and oversight.」

    The appointment of 3 outside directors is intended to strengthen transparency and oversight by drawing on their independence and expertise.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet. It last moved in the General Meetings of Shareholders of 2026-05-28: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Oversight by Outside Directors | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori